Total Liabilities Summary of Genmab A/S

Genmab A/S's latest annual total liabilities in 2023 was 3.67 Billion DKK , up 29.68% from previous year.
Genmab A/S's latest quarterly total liabilities in 2024 Q2 was 7.65 Billion DKK , up 82.88% from previous quarter.
Genmab A/S reported annual total liabilities of 2.83 Billion DKK in 2022, up 16.7% from previous year.
Genmab A/S reported annual total liabilities of 2.43 Billion DKK in 2021, up 20.23% from previous year.
Genmab A/S reported quarterly total liabilities of 7.65 Billion DKK for 2024 Q2, up 82.88% from previous quarter.
Genmab A/S reported quarterly total liabilities of 3.2 Billion DKK for 2023 Q1, up 12.94% from previous quarter.

Annual Total Liabilities Chart of Genmab A/S (2023 - 2002)

Historical Annual Total Liabilities of Genmab A/S (2023 - 2002)

Year	Total Liabilities	Total Liabilities Growth
2023	3.67 Billion DKK	29.68%
2022	2.83 Billion DKK	16.7%
2021	2.43 Billion DKK	20.23%
2020	2.02 Billion DKK	84.49%
2019	1.09 Billion DKK	145.39%
2018	446.63 Million DKK	35.04%
2017	330.75 Million DKK	-19.63%
2016	411.54 Million DKK	-1.03%
2015	415.82 Million DKK	-50.13%
2014	833.74 Million DKK	-22.23%
2013	1.07 Billion DKK	-18.15%
2012	1.3 Billion DKK	21.49%
2011	1.07 Billion DKK	-23.08%
2010	1.4 Billion DKK	51.63%
2009	924.34 Million DKK	-13.64%
2008	1.07 Billion DKK	-0.48%
2007	1.07 Billion DKK	445.81%
2006	197.04 Million DKK	-21.7%
2005	251.66 Million DKK	176.79%
2004	90.92 Million DKK	-2.94%
2003	93.67 Million DKK	-49.08%
2002	183.96 Million DKK	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	4.18 Billion DKK	13.7%
2024 Q2	7.65 Billion DKK	82.88%
2023 Q1	3.2 Billion DKK	12.94%
2023 Q2	3.22 Billion DKK	0.59%
2023 Q3	4.12 Billion DKK	28.02%
2023 FY	3.67 Billion DKK	29.68%
2023 Q4	3.67 Billion DKK	-10.83%
2022 Q4	2.83 Billion DKK	-29.59%
2022 Q1	2.19 Billion DKK	-9.71%
2022 Q2	2.99 Billion DKK	36.4%
2022 Q3	4.02 Billion DKK	34.57%
2022 FY	2.83 Billion DKK	16.7%
2021 Q1	2.11 Billion DKK	4.6%
2021 FY	2.43 Billion DKK	20.23%
2021 Q4	2.43 Billion DKK	-9.96%
2021 Q2	2.23 Billion DKK	5.48%
2021 Q3	2.7 Billion DKK	21.02%
2020 FY	2.02 Billion DKK	84.49%
2020 Q1	905 Million DKK	-17.43%
2020 Q2	2.81 Billion DKK	210.72%
2020 Q3	3.04 Billion DKK	8.29%
2020 Q4	2.02 Billion DKK	-33.6%
2019 Q1	607.55 Million DKK	36.03%
2019 Q4	1.09 Billion DKK	34.37%
2019 FY	1.09 Billion DKK	145.39%
2019 Q2	690.8 Million DKK	13.7%
2019 Q3	815.67 Million DKK	18.08%
2018 Q3	324.56 Million DKK	-4.1%
2018 Q1	263.01 Million DKK	-20.48%
2018 FY	446.63 Million DKK	35.04%
2018 Q4	446.63 Million DKK	37.61%
2018 Q2	338.43 Million DKK	28.68%
2017 Q3	428.34 Million DKK	-27.3%
2017 Q2	589.16 Million DKK	47.52%
2017 Q1	399.37 Million DKK	-2.96%
2017 FY	330.75 Million DKK	-19.63%
2017 Q4	330.75 Million DKK	-22.78%
2016 Q2	379.65 Million DKK	-2.62%
2016 Q1	389.88 Million DKK	-6.24%
2016 Q3	418.94 Million DKK	10.35%
2016 Q4	411.54 Million DKK	-1.77%
2016 FY	411.54 Million DKK	-1.03%
2015 FY	415.82 Million DKK	-50.13%
2015 Q4	415.82 Million DKK	-9.99%
2015 Q3	461.96 Million DKK	-10.15%
2015 Q2	514.14 Million DKK	-12.43%
2015 Q1	587.09 Million DKK	-29.58%
2014 Q1	1.02 Billion DKK	-4.16%
2014 FY	833.74 Million DKK	-22.23%
2014 Q4	833.74 Million DKK	-7.09%
2014 Q3	897.32 Million DKK	-7.25%
2014 Q2	967.49 Million DKK	-5.83%
2013 FY	1.07 Billion DKK	-18.15%
2013 Q2	1.17 Billion DKK	-6.84%
2013 Q3	1.28 Billion DKK	8.8%
2013 Q4	1.07 Billion DKK	-16.49%
2013 Q1	1.26 Billion DKK	-3.29%
2012 Q1	1.03 Billion DKK	-4.23%
2012 FY	1.3 Billion DKK	21.49%
2012 Q3	1.4 Billion DKK	39.96%
2012 Q4	1.3 Billion DKK	-6.7%
2012 Q2	1 Billion DKK	-2.85%
2011 Q2	1.17 Billion DKK	-5.78%
2011 Q4	1.07 Billion DKK	-5.28%
2011 Q3	1.13 Billion DKK	-2.92%
2011 FY	1.07 Billion DKK	-23.08%
2011 Q1	1.24 Billion DKK	-11.22%
2010 Q4	1.4 Billion DKK	6.85%
2010 Q1	867.41 Million DKK	-6.16%
2010 FY	1.4 Billion DKK	51.63%
2010 Q2	750.68 Million DKK	-13.46%
2010 Q3	1.31 Billion DKK	74.73%
2009 Q4	924.34 Million DKK	0.0%
2009 FY	924.34 Million DKK	-13.64%
2008 FY	1.07 Billion DKK	-0.48%
2007 FY	1.07 Billion DKK	445.81%
2006 FY	197.04 Million DKK	-21.7%
2005 FY	251.66 Million DKK	176.79%
2004 FY	90.92 Million DKK	-2.94%
2003 FY	93.67 Million DKK	-49.08%
2002 FY	183.96 Million DKK	0.0%

Peer Total Liabilities Comparison of Genmab A/S

Name	Total Liabilities	Total Liabilities Difference
ALK-Abelló A/S	2.27 Billion DKK	-61.43%
Bavarian Nordic A/S	4.01 Billion DKK	8.329%
Gubra A/S	145.62 Million DKK	-2426.421%
Novo Nordisk A/S	207.92 Billion DKK	98.231%
Orphazyme A/S	5.07 Million DKK	-72464.103%
Pharma Equity Group A/S	42.4 Million DKK	-8576.068%
Zealand Pharma A/S	1.6 Billion DKK	-129.074%

Global Stocks Search

Genmab A/S (GMAB.CO)

Total Liabilities Summary of Genmab A/S

Annual Total Liabilities Chart of Genmab A/S (2023 - 2002)

Historical Annual Total Liabilities of Genmab A/S (2023 - 2002)

Peer Total Liabilities Comparison of Genmab A/S